These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9684921)

  • 41. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
    Bandele OJ; Osheroff N
    Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
    Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance?
    McKenna SL; Whittaker JA; Padua RA; Holmes JA
    Leukemia; 1993 Aug; 7(8):1199-203. PubMed ID: 8394482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
    Bender RP; Lindsey RH; Burden DA; Osheroff N
    Biochemistry; 2004 Mar; 43(12):3731-9. PubMed ID: 15035644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
    Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
    NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insights into leukemogenesis from therapy-related leukemia.
    Pedersen-Bjergaard J
    N Engl J Med; 2005 Apr; 352(15):1591-4. PubMed ID: 15829541
    [No Abstract]   [Full Text] [Related]  

  • 48. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
    Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
    Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
    Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome.
    McKenna SL; West RR; Whittaker JA; Padua RA; Holmes JA
    Leukemia; 1994 Sep; 8(9):1498-502. PubMed ID: 8090029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
    Rossman J; Reddy V; Cantor A; Miley D; Robert F
    Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From DNA damage to G2 arrest: the many roles of topoisomerase II.
    Larsen AK; Escargueil AE; Skladanowski A
    Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
    Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
    Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA topoisomerase II as a target for cancer chemotherapy.
    Walker JV; Nitiss JL
    Cancer Invest; 2002; 20(4):570-89. PubMed ID: 12094551
    [No Abstract]   [Full Text] [Related]  

  • 58. Topoisomerases: novel therapeutic targets in cancer chemotherapy.
    Hsiang YH; Wu HY; Liu LF
    Biochem Pharmacol; 1988 May; 37(9):1801-2. PubMed ID: 2837240
    [No Abstract]   [Full Text] [Related]  

  • 59. New model for drug development needed in leukaemia.
    Nierengarten MB
    Lancet Oncol; 2006 Nov; 7(11):893. PubMed ID: 17099982
    [No Abstract]   [Full Text] [Related]  

  • 60. [Sensitivity tests of human malignant tumors to cytostatic drugs].
    Kaufmann M; Volm M; Goerttler K
    Klin Wochenschr; 1971 Feb; 49(4):219-23. PubMed ID: 5100884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.